4547.T Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 bal. 2024 @ 03:02):

Stats
Šios dienos apimtis	2 500.00
Vidutinė apimtis	93 465.00
Rinkos kapitalizacija	159.14B
EPS	¥0 ( 2024-01-30 )
Kita pelno data	( ¥110.76 ) 2024-05-06
Last Dividend	¥40.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	13.42
ATR14	¥3.37 (0.09%)

Tūris Koreliacija

Ilgas: 0.07 (neutral)

Trumpas: -0.64 (weak negative)

Signal:(49.743) Neutral

Kissei Pharmaceutical Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Kissei Pharmaceutical Koreliacija - Valiuta/Žaliavos

-0.52
( weak negative )

0.65
( moderate )

0.39
( neutral )

-0.46
( neutral )

0.67
( moderate )

0.56
( weak )

Kissei Pharmaceutical Finansinės ataskaitos

Annual	2022
Pajamos:	¥67.49B
Bruto pelnas:	¥32.38B (47.97 %)
EPS:	¥228.30

FY	2022
Pajamos:	¥67.49B
Bruto pelnas:	¥32.38B (47.97 %)
EPS:	¥228.30

FY	2022
Pajamos:	¥65.38B
Bruto pelnas:	¥31.24B (47.78 %)
EPS:	¥280.20

FY	2021
Pajamos:	¥69.04B
Bruto pelnas:	¥32.72B (47.39 %)
EPS:	¥113.25

Financial Reports:

No articles found.

Kissei Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥40.00 (N/A)	¥0 (N/A)	¥40.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Kissei Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.36 - Stable (12.73%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥7.00	2001-03-27
Last Dividend	¥40.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	46	--
Total Paid Out	¥794.00	--
Avg. Dividend % Per Year	0.00%	--
Score	3.68	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.36
Div. Directional Score	7.40	--

Next Divdend (Est)
(2024-07-03)

¥0 Estimate 1.26 %

Dividend Stability

0.10 Bad

Dividend Score

3.68

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8600.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
8182.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7564.T	Ex Dividend Knight	2024-03-28	Annually	0.00%
6768.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6104.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
4820.T	Ex Dividend Junior	2023-12-28	Semi-Annually	0.00%
4028.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
3245.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
2270.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
9107.T	Ex Dividend Junior	2023-09-28	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.165	1.500	6.69	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0534	1.200	8.22	9.86	[0 - 0.3]
returnOnEquityTTM	0.0620	1.500	-0.422	-0.634	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	5.93	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.22	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.155	1.500	4.69	7.04	[0.2 - 2]
debtRatioTTM	0.00608	-1.500	9.90	-10.00	[0 - 0.6]
interestCoverageTTM	141.28	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	186.97	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	186.97	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.00707	-1.500	9.97	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.482	1.000	5.29	5.29	[0.2 - 0.8]
operatingProfitMarginTTM	0.0345	1.000	-1.310	-1.310	[0.1 - 0.6]
cashFlowToDebtRatioTTM	6.04	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.323	0.800	-1.182	-0.946	[0.5 - 2]
Total Score				10.43

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	13.21	1.000	8.77	0	[1 - 100]
returnOnEquityTTM	0.0620	2.50	-0.272	-0.634	[0.1 - 1.5]
freeCashFlowPerShareTTM	186.97	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	2.29	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	186.97	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0896	1.500	-2.74	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.114	1.000	9.65	0	[0.1 - 0.5]
Total Score				4.36

Kissei Pharmaceutical

Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. The company's products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. It is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was founded in 1946 and is headquartered in Matsumoto, Japan.